PTC Therapeutics, Inc.
NASDAQ:PTCTBiotechnology
+$0.60 today
- Market cap
- $5.03B
- Beta
- 0.55
- P/E (TTM)
- -35.0
- EPS (TTM)
- -$2.26
Volume 0.64M
Average 1.27M
PTCT Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
PTC Therapeutics, Inc.NASDAQ: PTCT
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $23.29M rose 25.6% year over year, ahead of the +15.0% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 0.6% from the prior quarter. Over 3 fiscal years it compounded at -12.3% a year.
Context
- Stock-based compensation amounted to 4.3% of revenue in FY2025, down 4.9 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +25.6% holds above the trailing-twelve-month pace of +15.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 74.55M USD
- Year-over-year change
- -0.1%
- 4-year CAGR
- -7.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 74.55M | -0.1% |
| FY2024 | 2024-12-31 | 74.62M | -43.1% |
| FY2023 | 2023-12-31 | 131.21M | +18.9% |
| FY2022 | 2022-12-31 | 110.33M | +6.6% |
| FY2021 | 2021-12-31 | 103.51M | — |
Stock-Based Compensation vs competitors
How PTCT compares with its peers on the latest reported figures
- PTCT's LTM Jun 2026 stock-based compensation of $84.66M is the 7th largest of the 11 companies compared; the peer median is $111.66M.
- Its year-over-year change of +15.0% is the 5th highest of 11, against a peer median of -1.3%.
- Stock-based compensation amounts to 8.4% of revenue for PTCT, versus a peer median of 15.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $172.73B | +92559.3% | -2.6% | 16.8% | |
| LTM Mar 2026 | $3.98B | +32410.1% | +56.9% | — | |
| LTM Mar 2026 | $142.83M | -11.3% | +5.5% | 21.3% | |
| LTM Sep 2026 | $132.29M | +4.4% | +10.1% | 13.8% | |
| LTM Jun 2026 | $111.95M | -7.0% | +13.3% | 15.7% | |
| LTM Mar 2026 | $111.37M | -39.8% | -19.1% | 5.1% | |
| LTM Jun 2026 | $84.66M | +15.0% | -12.3% | 8.4% | |
| LTM Jun 2026 | $41.53M | -23.5% | +17.9% | 9.4% | |
| LTM Jun 2026 | $39.28M | -8.1% | +44.6% | — | |
| LTM Mar 2026 | $21.73M | +42.8% | — | 30.3% | |
| LTM Mar 2026 | $18.73M | +52.9% | +30.9% | — | |
| Peer median (excluding PTCT) | $111.66M | -1.3% | +13.3% | 15.7% | |
Competitors are the stored peer set for PTCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (523.9M) | (559.02M) | (626.6M) | (363.3M) | 682.64M |
| Depreciation & Amortization | 64.13M | 128.84M | 236.59M | 75.66M | 38.82M |
| Deferred Income Tax | 377K | (34.28M) | (46.93M) | (55.91M) | (3K) |
| Stock-Based Compensation | 103.51M | 110.33M | 131.21M | 74.62M | 74.55M |
| Change in Working Capital | (23.79M) | (85.34M) | (4M) | 102.54M | (47.88M) |
| Accounts Receivables | (44.99M) | (48.47M) | (1.54M) | 1.73M | (10.15M) |
| Inventory | 1.8M | (6.67M) | (8.18M) | 6.16M | (53.9M) |
| Accounts Payables | 23.41M | 27.54M | 0 | 0 | 0 |
| Other Working Capital | (4.01M) | (57.74M) | 5.72M | 94.65M | 16.17M |
| Other Non-Cash Items | 128.33M | 82.81M | 151.32M | 58.7M | (36.93M) |
| Operating Cash Flow | (251.33M) | (356.65M) | (158.42M) | (107.69M) | 711.2M |
| Capital Expenditures | (85.33M) | (152.46M) | (120.62M) | (74.25M) | (300.01M) |
| Acquisitions (Net) | 57.12M | 128.44M | 0 | 0 | 0 |
| Purchases of Investments | (543.27M) | (75.55M) | (212.48M) | (667.36M) | (1.42B) |
| Sales of Investments | 847.78M | 518.19M | 156.37M | 607.74M | 855.12M |
| Other Investing Activities | (57.12M) | (128.44M) | (92.18M) | 110.31M | (291.08M) |
| Investing Cash Flow | 219.18M | 290.18M | (176.74M) | 44.18M | (861.98M) |
| Debt Repayment | (2.22M) | 148.72M | (301.38M) | (1.49M) | (1.61M) |
| Common Stock Issued | 23.1M | 50M | 0 | 0 | 99.05M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (30.77M) | 947.78M | 257.36M | 233.66M |
| Financing Cash Flow | 20.88M | 167.95M | 646.4M | 255.87M | 331.09M |
| Effect of Forex Changes | (7.82M) | (2.77M) | 3.11M | (7.33M) | 22.71M |
| Net Change in Cash | (19.09M) | 98.71M | 314.36M | 185.03M | 203.02M |
| Free Cash Flow | (336.66M) | (509.11M) | (279.04M) | (181.94M) | 411.18M |
PTC Therapeutics, Inc.
NASDAQ:PTCT
Intrinsic Alpha fair value
Locked
Current Price
$60.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.